Literature DB >> 8291368

Blood proteins C and S in sickle cell disease.

M A el-Hazmi1, A S Warsy, H Bahakim.   

Abstract

Proteins C and S are vitamin K-dependent proteins with an essential anti-coagulant function. Protein C exists in an inactive form and is activated by a thrombin-thrombomodulin complex. Protein S combines with protein C and forms a stoichiometric complex which regulates coagulation in the presence of calcium. As patients with sickle cell disease (SCD) bear a high risk of developing thrombo-embolic disorders, we studied the coagulation derangement in 100 patients and 40 normal age- and sex-matched controls. The patients were clinically assessed and classified into sickle cell homozygotes (Hb SS), Hb S heterozygotes (Hb AS) and double heterozygotes for Hb S/beta 0-thalassaemia based on haematological parameters, red cell indices, Hb A2 and F levels and genetic studies. The proteins C and S were estimated and related to the type of the gene defect. The results showed significantly reduced levels of proteins C and S in SCD patients with the highest prevalence of deficiency in patients with a severe disease and frequent episodes of crisis. However, no significant differences were encountered in the level of proteins C and S in the same patients during the steady state and during episodes of crisis. It was concluded that the lower protein C and S levels in SCD is either due to decreased production or increased consumption though this reduction does not seem to play a role in producing thrombo-embolic disorders.

Entities:  

Mesh:

Year:  1993        PMID: 8291368     DOI: 10.1159/000204390

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  9 in total

Review 1.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 2.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 3.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

4.  Sickle cell disease and venous thromboembolism.

Authors:  Zohreh Rahimi; Abbas Parsian
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-05-24       Impact factor: 2.576

5.  Serum homocysteine and disease severity in sickle cell anemia patients in Lagos.

Authors:  Ebele Uche; Oluwaseun Adelekan; Akinsegun Akinbami; Vincent Osunkalu; Kamal Ismail; Ann Abiola Ogbenna; Mulikat Badiru; Adedoyin Dosunmu; Esther Oluwole; Omolara Kamson
Journal:  J Blood Med       Date:  2019-05-08

6.  Comparative study of hypercoagulability change in steady state and during vaso-occlusive crisis among Sudanese patients living with sickle cell disease.

Authors:  Elmigdad Abdelgadir Mohamed; Mamoud Mohamed Elgari; Asaad Mohammed Babker; Hisham Ali Waggiallah
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

Review 7.  Linking Labile Heme with Thrombosis.

Authors:  Marie-Thérèse Hopp; Diana Imhof
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

Review 8.  Protein S: function, regulation, and clinical perspectives.

Authors:  Rinku Majumder; Tina Nguyen
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

9.  Methylene tetrahydrofolate reductase gene mutation in sickle cell anaemia patients in Lagos, Nigeria.

Authors:  Oluwaseun Olabisi Adelekan; Ebele Ifeyinwa Uche; Taiwo Modupe Balogun; Vincent Oluseye Osunkalu; Akinsegun Abduljaleel Akinbami; Kamal Ayobami Ismail; Mulikat Adesola Badiru; Adedoyin Owolabi Dosunmu; Omolara Risqat Kamson
Journal:  Pan Afr Med J       Date:  2019-12-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.